Target intelligence / Profile preview

Gastric mucus

Molecular classification
Other (glycoprotein secretion; not a receptor, enzyme, channel, or transporter)
01

Overview

Gastric mucus is a viscous secretion composed primarily of glycoproteins called mucins—mainly derived from mucous neck cells—which forms a thick layer over the gastric epithelium[3][7][8]. Its main functions are protecting the stomach lining from corrosive gastric acid and digestive enzymes by acting as a physical and pH buffer barrier and lubricating the food bolus for effective digestion and transit[1][3][7][8]. The mucus gel traps bicarbonate ions at the epithelial surface, maintaining a neutral microenvironment even as the gastric lumen remains highly acidic[3]. Disruption of the mucus barrier is implicated in peptic ulcers, gastritis, and certain forms of gastric cancer[2][3][6]; enhancement of mucus integrity is a pharmacological goal in gastric protective therapy.

Other names
Gastric mucous layerGastric protective mucusStomach mucusNull for molecular synonyms (no accepted gene/protein aliases)
02

Mechanism of action

Enhanced mucus secretion and cytoprotection (misoprostol, sucralfate) Acid inhibition (PPIs reduce the need for extreme mucus protection) Disruption of mucus biosynthesis (NSAIDs block prostaglandin-mediated mucus secretion)

03

Biological functions

Lubrication of stomach contentsProtection of gastric epithelium from acid, enzymes, and physical abrasionMaintenance of a pH gradient between gastric lumen and epithelial surfaceEntrapment of pathogens and modulation of immune responsesBarrier to infection and chemical injuryChyme formation assistance
04

Disease associations

Peptic ulcer (mucus barrier deficiency contributes)GastritisHelicobacter pylori infectionGastric cancer (mucin changes in neoplasia)InflammationOther: Polyps, fibrosis, autoimmune mucosal diseases
05

Safety considerations

Barrier disruption can lead to ulceration and increased susceptibility to gastric injuryDrug-induced impairment (e.g. NSAIDs increasing ulcer risk)Excess mucus production in malignancy may affect digestion
06

Interacting drugs

Sucralfate

3 more in the full profile.

07

Biomarkers

Mucin subtypes (e.g. MUC5AC upregulation in gastric neoplasms)Bicarbonate concentration in mucusMucosal thickness (histological assessment)

Beyond the preview

Go deeper on Gastric mucus.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gastric mucus.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call